Research Paper Volume 15, Issue 7 pp 2734—2771

Comprehensive analysis reveals TSEN54 as a robust prognosis biomarker and promising immune-related therapeutic target for hepatocellular carcinoma

Bidong Fu1,2, *, , Minqin Zhou2, *, , Gelin Song2, *, , Hong Zeng2, , Yiyang Gong2, , Yike Jiang2, , Yun Ke2, , Da Huang3, , Hong Peng4, &, , Qing Li1, ,

  • 1 Department of Pathology, Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, People’s Republic of China
  • 2 Second College of Clinical Medicine, Nanchang University, Nanchang, Jiangxi Province, People’s Republic of China
  • 3 Department of Thyroid Surgery, Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, People’s Republic of China
  • 4 Department of Colorectal Surgery, 908th Hospital of Chinese People’s Liberation Army Joint, Nanchang, Jiangxi Province, People’s Republic of China
* Equal contribution

Received: December 16, 2022       Accepted: March 17, 2023       Published: April 8, 2023
How to Cite

Copyright: © 2023 Fu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Background: Hepatocellular carcinoma represents the most common primary malignancy of all liver cancer types and its prognosis is usually unsatisfactory. TSEN54 encodes a protein constituting a subunit of the tRNA splicing endonuclease heterotetramer. Previous researches concentrated on the contribution of TSEN54 in pontocerebellar hypoplasia, but no studies have yet reported its role in HCC.

Methods: TIMER, HCCDB, GEPIA, HPA, UALCAN, MEXPRESS, SMART, TargetScan, RNAinter, miRNet, starBase, Kaplan-Meier Plotter, cBioPortal, LinkedOmics, GSEA, TISCH, TISIDB, GeneMANIA, PDB, GSCALite were applied in this research.

Results: We identified the upregulation of TSEN54 expression in HCC and related it to multiple clinicopathological features. Hypomethylation of TSEN54 was closely associated with its high expression. HCC sufferers who held high TSEN54 expression typically had shorter survival expectations. Enrichment analysis showed the involvement of TSEN54 in the cell cycle and metabolic processes. Afterward, we observed that TSEN54 expression level had a positive relationship to the infiltration level of multiple immune cells and the expression of several chemokines. We additionally identified that TSEN54 was related to the expression level of several immune checkpoints and TSEN54 was linked to several m6A-related regulators.

Conclusions: TSEN54 is a prognostic marker of HCC. TSEN54 could become a prospective candidate for HCC diagnosis and therapy.


TCGA: The Cancer Genome Atlas; GTEx: Genotype-Tissue Expression Project; GSEA: Gene set enrichment analysis; TIICs: Tumor infiltrating immune cells; ROC: Receiver operating characteristic curve; AUC: Area under curve; m6A: N6-methyladenosine; CNV: Copy number variation; HCC: Hepatocellular carcinoma.